20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Attovia Therapeutics, Inc. Common Stock (ATTO) operates in the BIOTECHNOLOGY industry and is headquartered in San Carlos, United States with about 44 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-12-31, ATTO reported $1M in revenue and ($61M) in net income.
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments.
Interactive charts & full statements → Open the ATTO valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 |
|---|---|---|---|
| Total Revenue | $0M | $1M | $0M |
| Gross Profit | — | $1M | $0M |
| Gross Margin % | — | 40.4% | — |
| Operating Income (EBIT) | ($74M) | ($67M) | ($42M) |
| Operating Margin % | -16551.6% | -4974.7% | — |
| Net Income | ($69M) | ($61M) | ($40M) |
| Net Margin % | -15318.4% | -4490.9% | — |
| EBITDA | — | ($66M) | ($41M) |
| Earnings Per Share (EPS) | — | $-1.41 | $-0.92 |
| Shares Outstanding (M) | 46M | 43M | 43M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M |
| Gross Profit | $0M | $0M | — | $0M |
| Gross Margin % | 45.3% | — | — | — |
| Operating Income (EBIT) | ($22M) | ($20M) | ($17M) | ($16M) |
| Operating Margin % | -4845.1% | — | — | — |
| Net Income | ($21M) | ($19M) | ($14M) | ($15M) |
| Net Margin % | -4597.1% | — | — | — |
| EBITDA | ($22M) | ($20M) | — | ($16M) |
| Earnings Per Share (EPS) | $-0.45 | $-0.48 | — | $-0.39 |
| Shares Outstanding (M) | 46M | 39M | — | 39M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 |
|---|---|---|---|
| Cash from Operations (CFO) | ($62M) | ($59M) | ($35M) |
| Capital Expenditures (CapEx) | $2M | $2M | $2M |
| Free Cash Flow (FCF) | ($64M) | ($62M) | ($37M) |
| FCF Margin % | -14194.7% | -4556.4% | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Cash from Operations (CFO) | ($17M) | ($18M) | ($13M) | ($14M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $2M |
| Free Cash Flow (FCF) | ($17M) | ($18M) | ($13M) | ($16M) |
| FCF Margin % | -3747.6% | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 |
|---|---|---|---|
| Total Assets | $128M | $166M | $77M |
| Cash & Cash Equivalents | $33M | $40M | $31M |
| Total Liabilities | $16M | $15M | $15M |
| Total Debt (Short + Long-Term) | $2M | $2M | $0M |
| Total Shareholders' Equity | $113M | $151M | $62M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ATTO viewer.
About TickerBase · Data methodology & sources · Privacy · Terms